Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 12;15(7):e41772.
doi: 10.7759/cureus.41772. eCollection 2023 Jul.

Stem Cell Therapy in Critical Limb Ischemia

Affiliations
Review

Stem Cell Therapy in Critical Limb Ischemia

Madhan Jeyaraman et al. Cureus. .

Abstract

Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the pre-existing compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles. SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated.

Keywords: amputation rates; critical limb ischemia; ischemia; mononuclear cells; stem cell.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Literature search per PRISMA guidelines
PRISMA-Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Figure 2
Figure 2. Regenerative principles of critical limb ischemia
Picture courtesy Dr. Madhan Jeyaraman

References

    1. Critical limb ischemia: current challenges and future prospects. Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R. Vasc Health Risk Manag. 2018;14:63–74. - PMC - PubMed
    1. The diagnostic classification of critical limb ischemia. Azuma N. Ann Vasc Dis. 2018;11:449–457. - PMC - PubMed
    1. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. Nehler MR, Duval S, Diao L, et al. J Vasc Surg. 2014;60:686–695. - PubMed
    1. Meta-analysis of the prevalence, incidence and natural history of critical limb ischemia. Biancari F. https://pubmed.ncbi.nlm.nih.gov/24126504/ J Cardiovasc Surg (Torino) 2013;54:663–669. - PubMed
    1. Management of critical limb ischemia. Kinlay S. Circ Cardiovasc Interv. 2016;9:0. - PMC - PubMed

LinkOut - more resources